MOG and neoplasm: This suggests that, when patients with post-transplant relapse are unable to achieve sufficient levels of GvATLL to eradicate tumor cells, blockade of Treg cells by MOG may lead to immune modulation to treat or prevent relapse without excessive toxicity.